Log in

Aldeyra Therapeutics Stock Price, News & Analysis (NASDAQ:ALDX)

$5.96
+0.12 (+2.05 %)
(As of 10/23/2019 05:58 AM ET)
Today's Range
$5.73
Now: $5.96
$6.10
50-Day Range
$4.41
MA: $5.49
$6.00
52-Week Range
$4.31
Now: $5.96
$12.79
Volume197,182 shs
Average Volume214,504 shs
Market Capitalization$164.38 million
P/E RatioN/A
Dividend YieldN/A
Beta0.86
Aldeyra Therapeutics, Inc, a biotechnology company, focuses on the development of products for inflammation, inborn errors of metabolism, and other diseases in the United States and internationally. It is developing ADX-102, a small molecule designed to trap and allow for the degradation of aldehydes, as well as ADX-103 and ADX-104 novel candidates for the treatment of noninfectious anterior uveitis, allergic conjunctivitis, dry eye syndrome, sjögren-larsson syndrome, and succinic semi-aldehyde dehydrogenase deficiency. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ALDX
CUSIPN/A
Phone781-761-4904

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$3.30 per share

Profitability

Net Income$-38,890,000.00

Miscellaneous

EmployeesN/A
Market Cap$164.38 million
Next Earnings Date11/13/2019 (Estimated)
OptionableOptionable

Receive ALDX News and Ratings via Email

Sign-up to receive the latest news and ratings for ALDX and its competitors with MarketBeat's FREE daily newsletter.


Aldeyra Therapeutics (NASDAQ:ALDX) Frequently Asked Questions

What is Aldeyra Therapeutics' stock symbol?

Aldeyra Therapeutics trades on the NASDAQ under the ticker symbol "ALDX."

How were Aldeyra Therapeutics' earnings last quarter?

Aldeyra Therapeutics, Inc (NASDAQ:ALDX) issued its quarterly earnings data on Thursday, August, 8th. The biotechnology company reported ($0.49) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.51) by $0.02. View Aldeyra Therapeutics' Earnings History.

When is Aldeyra Therapeutics' next earnings date?

Aldeyra Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, November 13th 2019. View Earnings Estimates for Aldeyra Therapeutics.

What price target have analysts set for ALDX?

3 equities research analysts have issued 1-year price targets for Aldeyra Therapeutics' shares. Their predictions range from $20.00 to $38.00. On average, they anticipate Aldeyra Therapeutics' share price to reach $30.33 in the next year. This suggests a possible upside of 408.9% from the stock's current price. View Analyst Price Targets for Aldeyra Therapeutics.

What is the consensus analysts' recommendation for Aldeyra Therapeutics?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aldeyra Therapeutics in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Aldeyra Therapeutics.

What are Wall Street analysts saying about Aldeyra Therapeutics stock?

Here are some recent quotes from research analysts about Aldeyra Therapeutics stock:
  • 1. According to Zacks Investment Research, "Aldeyra Therapeutics, Inc. is a biotechnology company. The company's products target immune-mediated, inflammatory, orphan, and other diseases. It is developing NS2, a compound that binds and traps free aldehydes. Aldeyra Therapeutics, Inc. is based in Burlington, Massachusetts. " (10/14/2019)
  • 2. Cantor Fitzgerald analysts commented, ": We reiterate our OW rating and raise the 12-month price target to $35/share from $30 following the announcement of the successful pivotal ALLEVIATE trial data in allergic conjunctivitis (AC)." (3/26/2019)

Has Aldeyra Therapeutics been receiving favorable news coverage?

Media stories about ALDX stock have been trending somewhat positive this week, according to InfoTrie Sentiment Analysis. The research firm identifies positive and negative media coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Aldeyra Therapeutics earned a coverage optimism score of 2.0 on InfoTrie's scale. They also gave press coverage about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the stock's share price in the immediate future. View News Stories for Aldeyra Therapeutics.

Are investors shorting Aldeyra Therapeutics?

Aldeyra Therapeutics saw a decline in short interest in September. As of September 30th, there was short interest totalling 959,300 shares, a decline of 5.0% from the August 30th total of 1,010,000 shares. Based on an average daily trading volume, of 194,000 shares, the days-to-cover ratio is currently 4.9 days. Approximately 4.0% of the company's stock are sold short. View Aldeyra Therapeutics' Current Options Chain.

Who are some of Aldeyra Therapeutics' key competitors?

What other stocks do shareholders of Aldeyra Therapeutics own?

Who are Aldeyra Therapeutics' key executives?

Aldeyra Therapeutics' management team includes the folowing people:
  • Dr. Todd C. Brady, Chief Exec. Officer, Pres and Director (Age 46)
  • Mr. Stephen J. Tulipano CPA, MBA, Chief Financial Officer and Treasurer (Age 59)
  • Dr. David J. Clark M.D., M.R.C.P., A.F.P.M., Chief Medical Officer (Age 53)
  • Ms. Mary Taylor M.P.H., Sr. VP of Regulatory Affairs (Age 59)

Who are Aldeyra Therapeutics' major shareholders?

Aldeyra Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Strs Ohio (0.11%) and Meeder Asset Management Inc. (0.04%). Company insiders that own Aldeyra Therapeutics stock include Ben Bronstein, David Mcmullin, Jesse I Treu, Joshua Reed, Richard Douglas and Todd C Brady. View Institutional Ownership Trends for Aldeyra Therapeutics.

Which major investors are selling Aldeyra Therapeutics stock?

ALDX stock was sold by a variety of institutional investors in the last quarter, including Strs Ohio. View Insider Buying and Selling for Aldeyra Therapeutics.

Which major investors are buying Aldeyra Therapeutics stock?

ALDX stock was purchased by a variety of institutional investors in the last quarter, including Meeder Asset Management Inc.. Company insiders that have bought Aldeyra Therapeutics stock in the last two years include Ben Bronstein, David Mcmullin, Joshua Reed, Richard Douglas and Todd C Brady. View Insider Buying and Selling for Aldeyra Therapeutics.

How do I buy shares of Aldeyra Therapeutics?

Shares of ALDX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Aldeyra Therapeutics' stock price today?

One share of ALDX stock can currently be purchased for approximately $5.96.

How big of a company is Aldeyra Therapeutics?

Aldeyra Therapeutics has a market capitalization of $164.38 million. The biotechnology company earns $-38,890,000.00 in net income (profit) each year or ($1.79) on an earnings per share basis. View Additional Information About Aldeyra Therapeutics.

What is Aldeyra Therapeutics' official website?

The official website for Aldeyra Therapeutics is http://www.ampliphibio.com/.

How can I contact Aldeyra Therapeutics?

Aldeyra Therapeutics' mailing address is 131 HARTWELL AVENUE SUITE 320, LEXINGTON MA, 02421. The biotechnology company can be reached via phone at 781-761-4904 or via email at [email protected]


MarketBeat Community Rating for Aldeyra Therapeutics (NASDAQ ALDX)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  338 (Vote Outperform)
Underperform Votes:  262 (Vote Underperform)
Total Votes:  600
MarketBeat's community ratings are surveys of what our community members think about Aldeyra Therapeutics and other stocks. Vote "Outperform" if you believe ALDX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ALDX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/23/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel